Glucokinase Activator Crystal Forms Balancing Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a stable solid form of the glucokinase activator (GKA) compound A, particularly its crystal form, to enhance drug properties such as activity, stability, and bioavailability for the treatment of diabetes mellitus and related metabolic disorders.
Innovation Solution
Development of crystal forms of the free state and pharmaceutically acceptable salts of compound A, including hydrochloride, maleate, naphthalene disulfonate, oxalate, and hydrobromide, which exhibit specific X-ray powder diffraction peaks and thermal properties, ensuring stability and effective conversion into HMS5552 in the body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compound A is used as glucokinase activator, then biological activity is improved, but stability in solid form deteriorates
Solution Approach 1:
The patent applies parameter changes by transforming compound A from an unstable solid form to a stable crystal form through controlled crystallization processes. This phase transition from amorphous or unstable solid to ordered crystal structure fundamentally changes the physical parameters (melting point, density, solubility) while preserving the molecular structure and biological activity. The crystal form exhibits enhanced stability during manufacture, storage, and transport.
Solution Approach 2:
The patent utilizes phase transitions by converting compound A from an unstable solid or amorphous state to a stable crystal state. The crystallization process involves nucleation and growth phases, where molecules organize into a repeating lattice structure. This phase transition resolves the contradiction by providing a solid form with both stability and retainable biological activity, as evidenced by the compound's ability to convert efficiently to HMS5552 in the body.
2Stability of the object's composition
If crystal form is developed, then stability is improved, but bioavailability may deteriorate
Solution Approach 1:
The patent optimizes the crystal form parameters to balance stability and bioavailability. By controlling crystallization conditions (solvent selection, temperature, pH), the patent produces a crystal form with specific lattice energy, surface area, and solubility characteristics. This parameter optimization ensures that while the crystal form provides enhanced stability during storage, it maintains adequate solubility and dissolution rate for bioavailability. The crystal form described retains the ability to convert efficiently to the active form HMS5552 in intestinal and small intestinal cells.
3Adaptability or versatility
If multiple salt forms are developed, then versatility is improved, but manufacturing complexity deteriorates
Solution Approach 1:
The patent applies segmentation by developing multiple discrete salt forms (hydrochloride, maleate, naphthalene disulfonate, oxalate, hydrobromide) of compound A, each with distinct crystal structures and properties. This segmentation allows selection of optimal salt forms for different pharmaceutical applications, formulations, and delivery systems. Each salt form can be independently characterized, purified, and manufactured according to specific requirements, thereby managing complexity through modular development rather than attempting to optimize a single universal form.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to a crystal form of a free state of (R)-3-(3-((S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoylamino)- 1H-pyrazol-1-yl)-2-hydroxypropylnicotinate (compound A) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and a preparation method thereof, and a use of the crystal form in the preparation of a medicament for treating diabetes and related symptoms.